REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer

[1]  Masato Nakamura,et al.  RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer , 2020 .

[2]  D. Rossini,et al.  Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. , 2020, Clinical colorectal cancer.

[3]  E. Oki,et al.  A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer , 2019, British Journal of Cancer.

[4]  Masato Nakamura.  Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial , 2018, Annals of Oncology.

[5]  R. Danesi,et al.  Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.

[6]  P. Gibbs,et al.  Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study , 2018, Clinical Cancer Research.

[7]  Y. Ohashi,et al.  Phase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial. , 2018, Annals of Oncology.

[8]  S. Stintzing.  Faculty Opinions recommendation of Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[9]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[10]  J. Tabernero,et al.  Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J. Meyerhardt,et al.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.

[12]  H. Bando.  The current status and problems confronted in delivering precision medicine in Japan and Europe. , 2017, Current problems in cancer.

[13]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Salazar,et al.  Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  K. Hess,et al.  Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response , 2015, BMC Cancer.

[16]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[17]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Angenendt,et al.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Hartmut Link,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[20]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[21]  F. D. De Braud,et al.  Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens , 2013, Cancer biology & therapy.

[22]  Susan Richman,et al.  Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial , 2013, The Lancet. Oncology.

[23]  A. Russo,et al.  Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[25]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[26]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[27]  Jeffrey W. Clark,et al.  Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. , 2012, The oncologist.

[28]  M. Saif,et al.  Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. , 2010, Clinical colorectal cancer.

[29]  S. Goodman,et al.  Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. , 2008, Gastroenterology.

[30]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.